Dr. Goy on CAR T-Cell Therapy Updates in Non-Hodgkin Lymphoma
Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses updates in CAR T-cell therapy that are being presented at the 2019 ASCO Annual Meeting.
Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses updates in CAR T-cell therapy that are being presented at the 2019 ASCO Annual Meeting.
Many of the studies presented at the 2019 ASCO Annual Meeting related to CAR T-cell therapy were trials in progress. However, one study that had data read out included a subset from the ZUMA-1 trial, which demonstrated promising efficacy and safety data in patients older than 65 years with axicabtagene ciloleucel (Yescarta). Moreover, in the TRANSCEND NHL 001 trial, lisocabtagene maraleucel, another CAR T-cell product, also demonstrated benefit in patients with relapsed/refractory mantle cell lymphoma.
In patients with relapsed/refractory central nervous system lymphoma, data also showed that CAR T-cell therapy is feasible and demonstrated preliminary activity.
